-=NVAX Price target raised to $53 from $43

Price target raised to $53 from $43 at B. Riley FBR, citing an increased probability for the success of co's NVX-CoV2373. Sees strength alongside various other names in the COVID-19 vaccine development space, including Moderna (MRNA), which surges following its release of interim clinical data for vaccine candidate mRNA-1273. Adding on to recent strength, the stock now breaks out to new multi-year highs on above 2x average volume.